| Literature DB >> 35155207 |
Fuquan Deng1,2,3, Xiaoyuan Li4, Fengjiao Yang4, Hongwei Sun5, Jianmin Yuan6, Qiang He6, Weifeng Xu2, Yongfeng Yang1,3, Dong Liang1,3, Xin Liu1,3, Greta S P Mok7, Hairong Zheng1,3, Zhanli Hu1,3.
Abstract
BACKGROUND: 68 Ga-prostate-specific membrane antigen (PSMA) PET/MRI has become an effective imaging method for prostate cancer. The purpose of this study was to use deep learning methods to perform low-dose image restoration on PSMA PET/MRI and to evaluate the effect of synthesis on the images and the medical diagnosis of patients at risk of prostate cancer.Entities:
Keywords: PET/MRI; deep learning; discrete wavelet transform; low-dose restoration; prostate
Year: 2022 PMID: 35155207 PMCID: PMC8825350 DOI: 10.3389/fonc.2021.818329
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Discrete-wavelet-transform neural network (DWTN), including (A) the structure of the DWTN network, (B) the structure of the densely connected residual (DCR) block, and (C) the structure of the residual block.
Objective indicators for LDPET images, synthesized FDPET images, MR prior-synthesized FDPET images, and target images.
| Image | PSNR | SSIM | NMSE | RCNR |
|---|---|---|---|---|
| 2.5% | 25.56±4.99 | 0.745±0.112 | 0.065±0.045 | 0.835±0.267 |
| 2.5%LDPET | 32.51±4.89 | 0.820±0.079 | 0.029±0.021 | 1.046±0.213 |
| 2.5%LDPET+MRI | 33.34±4.47 | 0.846±0.060 | 0.026±0.018 | 1.118±0.218 |
| 5% | 26.99±5.56 | 0.756±0.113 | 0.057±0.037 | 0.860±0.227 |
| 5%LDPET | 33.25±4.57 | 0.814±0.137 | 0.026±0.018 | 1.032±0.216 |
| 5%LDPET+MRI | 33.78±4.25 | 0.817±0.141 | 0.024±0.017 | 0.964±0.248 |
| 25% | 29.58±7.05 | 0.832±0.114 | 0.047±0.036 | 0.901±0.195 |
| 25%LDPET | 36.90±4.40 | 0.893±0.090 | 0.017±0.012 | 1.035±0.123 |
| 25%LDPET+MRI | 37.86±4.16 | 0.916±0.063 | 0.015±0.012 | 1.004±0.126 |
| 50% | 32.02±8.66 | 0.865±0.123 | 0.040±0.036 | 0.909±0.183 |
| 50%LDPET | 39.48±3.90 |
| 0.012±0.008 | 1.009±0.079 |
| 50%LDPET+MRI |
| 0.896±0.092 |
|
|
In bold: The best performance in this indicator.
Figure 2NMSE and SSIM of the original LDPET images, synthetic FDPET images, and MR prior-synthesized FDPET images at all doses, where blue represents SSIM, orange represents NMSE, and different degrees of color represent images of different doses.
Figure 3The original LDPET images, synthesized FDPET images, MR prior-synthesized FDPET images of all doses, and their ROIs.
Figure 4Synthesized FDPET image, MR prior for all doses, combined FDPET image and target subtraction difference map and original image.
Figure 5MR and PET images of 6 patients with prostate or pelvic lesions from the test set. The MR sequences included DW-, ADC- and T2-weighted images. The PET images consist of the original FDPET images, FDPET images synthesized from 50%-dose images with MR priors, FDPET images synthesized from 50%-dose images without MR priors, and FDPET images synthesized from 25%-dose images with MR priors.
Mean clinical quantitative scores from nuclear medicine doctors on LDPET images, synthesized FDPET images, MR prior-synthesized FDPET images, and target images.
| Original | LDPET | LDPET+MRI | |
|---|---|---|---|
| 2.5% | 1.00±0.00 | 2.44±0.56 | 2.69±0.46 |
| 5% | 1.69±0.46 | 2.94±0.43 | 3.28±0.57 |
| 25% | 2.47±0.50 | 3.62±0.48 | 3.84±0.36 |
| 50% | 3.03±0.39 | 4.03±0.17 | 4.03±0.17 |
| 100% | 3.94±0.24 | – | – |
Figure 6Distribution of clinical quantitative scores from nuclear medicine doctors on LDPET images, synthesized FDPET images, MR prior-synthesized FDPET images, and target images.